| Title |
Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia
|
|---|---|
| Published in |
Biologics: Targets & Therapy, February 2015
|
| DOI | 10.2147/btt.s61600 |
| Pubmed ID | |
| Authors |
Sonia Cerquozzi, Carolyn Owen |
| Abstract |
The introduction of targeted therapy against CD20(+) with the monoclonal antibody rituximab has dramatically improved the survival of B-cell non-Hodgkin lymphoma including chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma. Unfortunately, CLL remains incurable with chemoimmunotherapy, with many patients having refractory or relapsing disease after rituximab-containing therapy. Obinutuzumab (GA101) is a novel humanized Type II anti-CD20 monoclonal antibody that has been investigated and compared to rituximab. Here, we provide an overview of obinutuzumab, including its mechanisms of action, preclinical data, and Phase I to III clinical studies. Preclinical data illustrate obinutuzumab's higher potency compared to rituximab through antibody-dependent cellular cytotoxicity and direct cell death. Recently, the CLL11 study presented a significant benefit from obinutuzumab chemoimmunotherapy and supports its use for treatment-naive unfit CLL patients. Herein, we review that obinutuzumab is both a safe and effective alternative to rituximab. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 1 | 6% |
| Belgium | 1 | 6% |
| Unknown | 16 | 89% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 22% |
| Other | 3 | 17% |
| Researcher | 3 | 17% |
| Student > Bachelor | 2 | 11% |
| Student > Doctoral Student | 1 | 6% |
| Other | 4 | 22% |
| Unknown | 1 | 6% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 44% |
| Agricultural and Biological Sciences | 4 | 22% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 17% |
| Biochemistry, Genetics and Molecular Biology | 1 | 6% |
| Mathematics | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 1 | 6% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 March 2015.
All research outputs
#17,286,645
of 25,374,917 outputs
Outputs from Biologics: Targets & Therapy
#192
of 284 outputs
Outputs of similar age
#222,304
of 361,176 outputs
Outputs of similar age from Biologics: Targets & Therapy
#3
of 3 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 284 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 361,176 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.